New Publication in Multiple Sclerosis Therapy
The results of the Phase 3 POINT study have just been published in Multiple Sclerosis and Related Disorders (July 2025), led by Prof. Ludwig Kappos and colleagues.
The study evaluated ponesimod as an add-on to dimethyl fumarate (DMF) in patients with active relapsing MS despite DMF monotherapy.
Key takeaways:
Premature termination of the study due to slow recruitment (136 of 600 planned patients enrolled) limits interpretation of the results.
Adding Ponesimod to dimethyl fumarate (DMF) was not superior to continuing on DMF in Relapsing multiple sclerosis.
Ponesimod+DMF treatment was associated with nominally lower MRI defined disease activity.
During the limited exposure to combined treatment no new safety concerns emerged.
Read full article here: https://www.msard-journal.com/article/S2211-0348(25)00358-X/abstract
